Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 2/20 | 0.42 |
| ▸ | NAAA | Q02083 | 2/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13417268 | 0.88 | FKBP1A (0.40) | FKBP1ANAAAHPGDKMT2AALDH1A1 | |
| SCHEMBL3318810 | 0.88 | ALDH1A1 (0.47) | HPGDSMN1; SMN2ALDH1A1NPSR1LMNA | |
| SCHEMBL3314282 | 0.84 | ALDH1A1 (0.44) | NAAAHPGDSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL14041443 | 0.84 | HPGD (0.37) | FKBP1ANAAAHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL3317400 | 0.81 | NAAA (0.41) | NAAA | |
| SCHEMBL14980950 | 0.81 | ALDH1A1 (0.39) | HPGDKMT2ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL3320876 | 0.80 | SMN1; SMN2 (0.41) | KMT2ASMN1; SMN2HTTLMNAMEN1 | |
| SCHEMBL3320884 | 0.79 | SMN1; SMN2 (0.42) | KMT2ASMN1; SMN2HTTLMNA | |
| SCHEMBL3316966 | 0.78 | KMT2A (0.41) | KMT2AALDH1A1TSHRNPSR1LMNA | |
| SCHEMBL4112246 | 0.78 | NPC1 (0.41) | HPGDKMT2ASMN1; SMN2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9199934-B2 | Alpha-hydroxyketones | BASF SE (DE) | 2015-12-01 | — | — | US | disclosed |
| US-9199934-B2 | Alpha-hydroxyketones | BASF SE (DE) | 2015-12-01 | — | — | US | disclosed |
| US-9199934-B2 | Alpha-hydroxyketones | BASF SE (DE) | 2015-12-01 | — | — | US | disclosed |
| EP-2129659-B1 | ALPHA-HYDROXYKETONES | BASF SE (DE) | 2013-05-29 | — | — | EP | disclosed |
| US-20100104979-A1 | ALPHA-HYDROXYKETONES | IGM GROUP B.V. (NL) | 2010-04-29 | — | — | US | disclosed |
| US-20100104619-A1 | DELIVERY SYSTEM FOR A NON-STEROIDAL NON-IONIZED HYDROPHILIC DRUG | N.V. ORGANON (NL) | 2010-04-29 | — | — | US | disclosed |
| US-20100104979-A1 | ALPHA-HYDROXYKETONES | IGM GROUP B.V. (NL) | 2010-04-29 | — | — | US | disclosed |
| US-20100104979-A1 | ALPHA-HYDROXYKETONES | IGM GROUP B.V. (NL) | 2010-04-29 | — | — | US | disclosed |
| EP-2129659-A1 | ALPHA-HYDROXYKETONES | BASF SE (DE) | 2009-12-09 | — | — | EP | disclosed |
| EP-2094348-A1 | DELIVERY SYSTEM FOR A NON-STEROIDAL NON-IONIZED HYDROPHILIC DRUG | N.V. Organon (NL) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008122504-A1 | ALPHA-HYDROXYKETONES | BASF SE (CH) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008122504-A1 | ALPHA-HYDROXYKETONES | BASF SE (CH) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008062008-A1 | DELIVERY SYSTEM FOR A NON-STEROIDAL NON-IONIZED HYDROPHILIC DRUG | N.V. ORGANON (NL) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104979-A1 | ALPHA-HYDROXYKETONES | C9, C1R, CBR3 | FKBP1A 2441/4885NAAA 3638/4885BCHE 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.